Parodi Katia, Paganetti Harald, Shih Helen A, Michaud Susan, Loeffler Jay S, DeLaney Thomas F, Liebsch Norbert J, Munzenrider John E, Fischman Alan J, Knopf Antje, Bortfeld Thomas
Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):920-34. doi: 10.1016/j.ijrobp.2007.01.063.
To investigate the feasibility and value of positron emission tomography and computed tomography (PET/CT) for treatment verification after proton radiotherapy.
This study included 9 patients with tumors in the cranial base, spine, orbit, and eye. Total doses of 1.8-3 GyE and 10 GyE (for an ocular melanoma) per fraction were delivered in 1 or 2 fields. Imaging was performed with a commercial PET/CT scanner for 30 min, starting within 20 min after treatment. The same treatment immobilization device was used during imaging for all but 2 patients. Measured PET/CT images were coregistered to the planning CT and compared with the corresponding PET expectation, obtained from CT-based Monte Carlo calculations complemented by functional information. For the ocular case, treatment position was approximately replicated, and spatial correlation was deduced from reference clips visible in both the planning radiographs and imaging CT. Here, the expected PET image was obtained from an analytical model.
Good spatial correlation and quantitative agreement within 30% were found between the measured and expected activity. For head-and-neck patients, the beam range could be verified with an accuracy of 1-2 mm in well-coregistered bony structures. Low spine and eye sites indicated the need for better fixation and coregistration methods. An analysis of activity decay revealed as tissue-effective half-lives of 800-1,150 s.
This study demonstrates the feasibility of postradiation PET/CT for in vivo treatment verification. It also indicates some technological and methodological improvements needed for optimal clinical application.
探讨正电子发射断层扫描与计算机断层扫描(PET/CT)用于质子放射治疗后治疗验证的可行性和价值。
本研究纳入9例颅底、脊柱、眼眶和眼部肿瘤患者。每次分割剂量为1.8 - 3 GyE,眼部黑色素瘤为10 GyE,在1或2个射野中给予。使用商用PET/CT扫描仪进行30分钟成像,在治疗后20分钟内开始。除2例患者外,所有患者在成像时均使用相同的治疗固定装置。将测量的PET/CT图像与计划CT进行配准,并与相应的PET预期值进行比较,PET预期值通过基于CT的蒙特卡罗计算并辅以功能信息获得。对于眼部病例,大致复制治疗位置,并从计划X线片和成像CT中可见的参考夹片推断空间相关性。在此,预期的PET图像通过分析模型获得。
在测量的和预期的活性之间发现了良好的空间相关性和30%以内的定量一致性。对于头颈部患者,在配准良好的骨性结构中,射野范围可精确到1 - 2毫米进行验证。脊柱下部和眼部显示需要更好的固定和配准方法。活性衰减分析显示组织有效半衰期为800 - 1150秒。
本研究证明了放射后PET/CT用于体内治疗验证的可行性。它还指出了最佳临床应用所需的一些技术和方法改进。